# Nuclide record prostate-mcrpc (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/prostate-mcrpc/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "prostate-mcrpc" ;
  schema:name "Metastatic castration-resistant prostate cancer"@en ;
  schema:alternateName "mCRPC"@en, "Metastatic CRPC"@en, "Castration-resistant metastatic prostate cancer"@en, "Hormone-refractory prostate cancer (older term)"@en ;
  schema:description "Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."@en ;
  schema:url <https://nuclide.cc/indications/prostate-mcrpc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Castration-resistant_prostate_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Castration-resistant_prostate_cancer>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459> ;
  nuclide:tag "subtype-page" ;
  nuclide:related <https://nuclide.cc/indications/prostate-mhspc/>, <https://nuclide.cc/indications/prostate-nmcrpc/>, <https://nuclide.cc/indications/prostate-nepc/>, <https://nuclide.cc/indications/prostate-bcr/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/>, <https://nuclide.cc/isotopes/ra-223/> ;
  nuclide:keyPapers <https://nuclide.cc/key-papers/paper-vision-nejm-2021/>, <https://nuclide.cc/key-papers/paper-alsympca-radium-223-nejm-2013/> ;
  nuclide:pipeline <https://nuclide.cc/drugs/ac225-psma/>, <https://nuclide.cc/drugs/lu177-psma-it/>, <https://nuclide.cc/drugs/fpi-2265/> ;
  nuclide:standardOfCare <https://nuclide.cc/drugs/abiraterone/>, <https://nuclide.cc/drugs/enzalutamide/>, <https://nuclide.cc/drugs/olaparib/>, <https://nuclide.cc/drugs/docetaxel/>, <https://nuclide.cc/drugs/olaparib/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/trials/psmafore/>, <https://nuclide.cc/drugs/pembrolizumab/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/drugs/cabazitaxel/>, <https://nuclide.cc/drugs/radium-223/>, <https://nuclide.cc/trials/alsympca/>, <https://nuclide.cc/trials/therap/>, <https://nuclide.cc/drugs/ac225-psma/>, <https://nuclide.cc/drugs/lu177-psma-it/>, <https://nuclide.cc/trials/alphabreak/>, <https://nuclide.cc/trials/splash/>, <https://nuclide.cc/trials/eclipse-psma/> .